Literature DB >> 15955734

Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

Neil Thompson1, John Lyons.   

Abstract

Since the discovery that activating mutations of the Ras GTPase were associated with 30% or more of human cancers, the RAF/MEK/ERK pathway has been the focus of intense drug discovery effort. Within the new class of molecularly targeted anti-cancer agents progressing through the late stages of clinical development, BAY 43-9006 and PD0325901 have shown considerable promise.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15955734     DOI： 10.1016/j.coph.2005.04.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  70 in total

Review 1.  Therapeutic targets in melanoma: map kinase pathway.

Authors:  Frank G Haluska; Nageatte Ibrahim
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

2.  A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.

Authors:  Kristine K Deibler; Rama K Mishra; Matthew R Clutter; Aleksandar Antanasijevic; Raymond Bergan; Michael Caffrey; Karl A Scheidt
Journal:  ACS Chem Biol       Date:  2017-03-20       Impact factor: 5.100

3.  Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.

Authors:  Qingqing Ding; Longfei Huo; Jer-Yen Yang; Weiya Xia; Yongkun Wei; Yong Liao; Chun-Ju Chang; Yan Yang; Chien-Chen Lai; Dung-Fang Lee; Chia-Jui Yen; Yun-Ju Rita Chen; Jung-Mao Hsu; Hsu-Ping Kuo; Chun-Yi Lin; Fuu-Jen Tsai; Long-Yuan Li; Chang-Hai Tsai; Mien-Chie Hung
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

4.  Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.

Authors:  Peng-Chieh Chen; Hiroko Wakimoto; David Conner; Toshiyuki Araki; Tao Yuan; Amy Roberts; Christine E Seidman; Roderick Bronson; Benjamin G Neel; Jonathan G Seidman; Raju Kucherlapati
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

5.  Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.

Authors:  Margaret A Park; Guo Zhang; Clint Mitchell; Mohamed Rahmani; Hossein Hamed; Michael P Hagan; Adly Yacoub; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

6.  Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.

Authors:  Jer-Yen Yang; Chun-Ju Chang; Weiya Xia; Yan Wang; Kwok-Kin Wong; Jeffrey A Engelman; Yi Du; Michael Andreeff; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

7.  ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.

Authors:  Jer-Yen Yang; Cong S Zong; Weiya Xia; Hirohito Yamaguchi; Qingqing Ding; Xiaoming Xie; Jing-Yu Lang; Chien-Chen Lai; Chun-Ju Chang; Wei-Chien Huang; Hsin Huang; Hsu-Ping Kuo; Dung-Fang Lee; Long-Yuan Li; Huang-Chun Lien; Xiaoyun Cheng; King-Jen Chang; Chwan-Deng Hsiao; Fuu-Jen Tsai; Chang-Hai Tsai; Aysegul A Sahin; William J Muller; Gordon B Mills; Dihua Yu; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Nat Cell Biol       Date:  2008-01-20       Impact factor: 28.824

8.  Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.

Authors:  Bin Zheng; Joseph H Jeong; John M Asara; Yuan-Ying Yuan; Scott R Granter; Lynda Chin; Lewis C Cantley
Journal:  Mol Cell       Date:  2009-01-30       Impact factor: 17.970

9.  Characterisation and germline transmission of cultured avian primordial germ cells.

Authors:  Joni Macdonald; James D Glover; Lorna Taylor; Helen M Sang; Michael J McGrew
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

10.  Using Caenorhabditis elegans as a model organism for evaluating extracellular signal-regulated kinase docking domain inhibitors.

Authors:  Fengming Chen; Alexander D Mackerell; Yuan Luo; Paul Shapiro
Journal:  J Cell Commun Signal       Date:  2008-12-23       Impact factor: 5.782
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.